CTIS2023-507516-12-00招募中1 期
A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid Tumors - TAS-120-206
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Provide written informed consent prior to any study-specific procedures and are willing to comply with all study procedures, Women of child-bearing potential (WOCBP) must have a negative pregnancy test. Female patients are not considered to be of child-bearing potential if they are permanently sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or are post-menopausal (no menses for 12 months without an alternative medical cause), Willing and able to comply with scheduled visits and study procedures, Is =18 years of age at the time of informed consent (or meets the country’s regulatory definition for legal adult age), Histologically or cytologically confirmed, locally advanced, unresectable or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the esophagogastric junction (EGJ), No prior systemic treatment for locally advanced, unresectable or metastatic esophageal carcinoma, Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1, 2009). A lesion(s) situated in a previously irradiated area can be considered a target lesion(s) if progression has been demonstrated and the lesion(s) is considered measurable per RECIST 1.1 criteria, Have documentation of PD-L1 CPS score, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, Have adequate organ function as exemplified in the protocol, Able to take medications orally
排除标准
- •Has locally advanced esophageal carcinoma that is resectable or potentially curable with radiation therapy (as determined by local investigator), Has known hypersensitivity or severe reaction to any of the study drugs or their excipients, including severe reaction to fluoropyrimidine therapy., Has received prior treatment with an anti-PD-1/PD-L1 or FGF/FGFR targeting drug, or any other agent directed to stimulatory or co-stimulatory T-cell receptor, Has known additional malignancy that is progressing or requires active treatment, with the exception of patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or antitumor assessment of the investigational regimen. Exceptions must be discussed with the Sponsor prior to patient enrollment, Has had treatment as defined in the protocol within the specified time frame prior to the first dose of study treatment, Has a serious illness or medical condition(s), Has a history or current evidence of calcium and phosphate homeostasis disorder or systemic mineral imbalance with ectopic calcification of soft tissues (except commonly observed calcifications in soft tissues such as the skin, kidney, tendons, or vessels due to injury, disease, and aging in the absence of systemic mineral imbalance), Has current evidence of clinically significant retinal disorder as confirmed by ophthalmological examination, Is pregnant or lactating female, Have a complete absence of dihydropyrimidine dehydrogenase (DPD) activity (blood uracil level =150ng/ml)., Has some safety specific values defined in the protocol for patients selected to receive oxaliplatin., Has an adenocarcinoma histology and is eligible to receive approved targeted therapy (eg, HER-2 positive patients)., Has some specific symptoms defined in the protocol for patients selected to receive cisplatin, Patients who have a persistent Grade =2 toxicity related to prior treatment., Exclusion only applicable for France, Exclusion only applicable for Germany, Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug, Has known human immunodeficiency virus (HIV) and/or history of Hepatitis B or C infections, or known to be positive for Hepatitis B antigen (HBsAg)/ Hepatitis B virus (HBV) DNA or Hepatitis C antibody or RNA. Active Hepatitis C virus (HCV) is defined by a known positive Hepatitis C antibody result and known quantitative HCV RNA results greater than the lower limits of detection of the assay, Has an active autoimmune disease that has required systemic treatment in the past 2 years (that is, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (for example, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed, Has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis, Has had an allogenic tissue/organ transplant, Is unable to swallow tablets/capsules or has any disease or condition that may significantly affect gastrointestinal absorption of futibatinib (eg, inflammatory bowel disease, malabsorption syndrome, or prior gastric/bowel resection), Is judged by the investigator to be ineligib
研究者
相似试验
招募中
2 期
A Phase 2 Study Evaluating Futibatinib (TAS-120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic bladder, urethra or pelvis cancer2024-513760-26-00Taiho Oncology Inc.15
进行中（未招募）
1 期
A Phase 2 Study Evaluating Futibatinib (TAS-120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic bladder, urethra or pelvis cancerAdvanced or Metastatic Urothelial CarcinomaMedDRA version: 20.0Level: LLTClassification code: 10064467Term: Urothelial carcinoma Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10077056Term: Urothelial carcinoma recurrent Class: 10029104CTIS2024-513760-26-00Taiho Oncology Inc.16
已完成
不适用
A phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with mutated EGFRnon-small-cell lung cancerJPRN-UMIN000004296Okayama Lung Cancer Study Group42
招募中
2 期
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or RearrangementAdvanced Cholangiocarcinoma Harboring FGFR2 Gene Fusion or RearrangementsJPRN-jRCT2051230018Elsayed Hamdy13
招募中
1 期
FOENIX-CCA4CTIS2023-503665-39-00Taiho Oncology Inc.120